Navigation Links
AbSci Appoints Biopharmaceutical Pioneer Dr. Fred Larimore to Executive Team
Date:8/21/2019

AbSci, a revolutionary synthetic biology company with a best-in-class E. coli cell line for rapid and low-cost biomanufacturing of complex protein therapeutics, today announced the appointment of Fred Larimore, PhD, to Vice President, Process Development. Formerly a member of AbSci's Scientific Advisory Board, Dr. Larimore brings more than 30 years of experience in biopharmaceutical manufacturing and process development at leading pharmaceutical companies including Cook Pharmica and Eli Lilly. As Head of Process Development, Dr. Larimore will ensure that AbSci technology will successfully scale from high-throughput research through industrial scale-up at CDMO and partner facilities.

In addition to announcing Dr. Larimore’s appointment, the company also revealed plans to add an additional 14 positions by the end of 2019 to meet growing demand for its innovative platform. AbSci is expanding its corporate headquarters, located in downtown Vancouver, Washington, that will include increased business office space and a significantly larger lab facility, bringing the company’s total square footage to more than 12,000.

“The SoluPro™ technology thus far holds no limits on capability and that’s why AbSci is truly the most exciting company in synthetic biology today,” said Dr. Larimore. “AbSci’s SoluPro™ Platform gives us the ability to disrupt the status quo and make next-generation biotherapeutics better, cheaper, faster, and safer than ever before. The affordability and availability of life-saving and life-changing therapies is very important to me and to every one of us at AbSci.”

Dr. Larimore worked for more than 25 years at Eli Lilly where he served as a Research Fellow and senior scientific leader. He has extensive experience in process design, development, scale-up, and manufacturing, and led manufacturing support of six major biotechnology products in the marketplace: Humulin®, Humalog®, Humatrope®, Forteo® and Recombinant Human Glucagon. He was influential in developing some of the original biologic manufacturing processes, including production of Human Insulin using the chain route (Humulin®), Human Insulin using the proinsulin process (Humulin®), Human Growth Hormone (Humatrope®), Recombinant Human Parathyroid Hormone (Forteo®), Factor IX and several other monoclonal antibodies.

Dr. Larimore is a founding member and Vice President of the Board of Directors of the Society for Bioprocessing Professionals (SBP) and currently serves as the Principal Consultant at Sierra Vista Biotech Consulting. He was also the Vice President of Scientific Affairs and Chief Scientific Officer of Cook Pharmica. Dr. Larimore holds a B.A. in Chemistry from St. Olaf College, a Ph.D. in Biochemistry from the University of Minnesota, and completed his post-doctoral training at the Harvard Medical School, Department of Physiology.

“We are honored to bring Dr. Larimore to our leadership team,” said Sean McClain, founder and CEO of AbSci. “He has been an invaluable contributor on our Scientific Advisory Board and we look forward to his continuing contributions as we rapidly expand our capabilities to service our large pharma and biotech clients. We’re also looking forward to making the Pacific Northwest, and more specifically the Portland/Vancouver area, a new center for biotechnology excellence as we build out our team and become the gold standard in biomanufacturing.”

To learn more about the positions currently available at AbSci, please visit the company’s Careers page.

About AbSci
AbSci is a global leader and innovator of revolutionary biomanufacturing technologies, designing and programming cells for next-generation biopharmaceuticals. AbSci’s biomanufacturing technology is the new gold standard in protein production, as it increases discovery throughput, accelerates development, reduces manufacturing costs, and increases plant capacity for the biopharmaceutical industry. Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides, to emerging novel classes of biotherapeutics. For more information, please visit http://www.absci.com.

Read the full story at https://www.prweb.com/releases/absci_appoints_biopharmaceutical_pioneer_dr_fred_larimore_to_executive_team/prweb16518996.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. uBiome Appoints John Rakow as Interim Chief Executive Officer
2. uBiome Appoints Dr. Julia Oh, PhD, Skin Microbiome Researcher, to its Scientific Advisory Board
3. NDA Partners Appoints Deb Koeneman as Partner in the Firm
4. Visikol Appoints Pharmaceutical Industry Leader, Stewart Hunt, as Director of US Sales
5. uBiome Appoints Dr. Amir Zarrinpar, MD, PhD, Assistant Professor in the Division of Gastroenterology at UC San Diego, to its Medical Advisory Board
6. uBiome Appoints Dr. Brandon Wuerth, MD, Founder of IBDwatch, to its Medical Advisory Board
7. uBiome Appoints Dr. Emeran Mayer, MD, World-Renowned Gastroenterologist and Neuroscientist, to its Medical Advisory Board
8. uBiome Appoints Dr. Jill Carnahan, MD, Functional Medicine Expert, to its Medical Advisory Board
9. uBiome Appoints Dr. Catherine Lozupone, PhD, Respected Microbiologist, to its Scientific Advisory Board
10. uBiome Appoints Leading Biochemist Dr. Joseph DeRisi to Board of Directors
11. uBiome Appoints Dr. Donnica Moore, MD, Women's Health Expert and Advocate, to its Medical Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2020)... ... July 01, 2020 , ... ... 1a findings of Neihulizumab, a biologic for the treatment of steroid-refractory acute graft-versus-host ... by hemato-oncologist Dr. Paul J Martin of the Fred Hutchinson Cancer Research Center, ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the ... clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers ...
(Date:6/28/2020)... ... June 25, 2020 , ... Genedata, ... that it has entered into a multi-year contract with Merus N.V., a ... translational and clinical research strategy to discover and develop ground-breaking drugs. The ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... BINGHAM FARMS, Mich. (PRWEB) , ... August 12, ... ... International Consulting Group, Inc. (EMMA International), a global leader in FDA compliance ... ranking of the nation’s fastest-growing private companies. The list represents a unique look ...
(Date:7/31/2020)... ... July 29, 2020 , ... G-CON Manufacturing, the leader in ... “BUILDING FOR LIFE.” The adoption of this taglines comes at a time of ... capacity to provide patients with urgently needed vaccines and other lifesaving pharmaceutical treatments. ...
(Date:7/31/2020)... ... July 29, 2020 , ... The ... centers in 16 countries, has reached its 20th anniversary of worldwide use. Introduced ... use at top universities including University of Pennsylvania, University of Michigan, University of ...
(Date:7/18/2020)... ... 2020 , ... Medial EarlySign , a leader in ... high-burden diseases, and Centric Consulting, a business and technology consulting firm, today announced ... in order to identify and prioritize patients for care. , Combining Centric’s management ...
Breaking Biology Technology: